Edwin C K Tan1, Johnson George, Kay Stewart, Rohan A Elliott. 1. Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia, edwin.tan@monash.edu.
Abstract
OBJECTIVE: The aim of the study was to evaluate the impact of a drug use evaluation (DUE) program on osteoporosis management in general practice. METHODS: A DUE program, led by pharmacists integrated into two general practice clinics in Melbourne, Australia, was undertaken as part of the Pharmacists in Practice Study. Data on use of anti-osteoporosis medicines and calcium and vitamin D supplements were collected at baseline and 12 months. Following the baseline audit, an intervention comprising prescriber feedback, group education and individual case-conferences with prescribers, and patient education mail-outs was implemented. The primary outcome was the proportion of patients with a diagnosis of osteoporosis and without contraindications to anti-osteoporosis medicines who were prescribed an anti-osteoporosis medicine. Feedback from practice staff and pharmacists was explored qualitatively to evaluate the acceptability of the program. RESULTS: The proportion of patients without documented contraindications to osteoporosis therapies who were prescribed an anti-osteoporosis medicine increased significantly (134/227 [59.0 %] vs. 168/240 [70.0 %], p = 0.002). The proportion of patients for whom vitamin D and/or calcium supplement use was documented also increased significantly (145/227 [63.9 %] vs. 205/240 [85.4 %], p = 0.002). Practice staff and pharmacists were generally positive about the DUE program. CONCLUSIONS: A practice pharmacist-led DUE program improved the management of osteoporosis in general practice.
OBJECTIVE: The aim of the study was to evaluate the impact of a drug use evaluation (DUE) program on osteoporosis management in general practice. METHODS: A DUE program, led by pharmacists integrated into two general practice clinics in Melbourne, Australia, was undertaken as part of the Pharmacists in Practice Study. Data on use of anti-osteoporosis medicines and calcium and vitamin D supplements were collected at baseline and 12 months. Following the baseline audit, an intervention comprising prescriber feedback, group education and individual case-conferences with prescribers, and patient education mail-outs was implemented. The primary outcome was the proportion of patients with a diagnosis of osteoporosis and without contraindications to anti-osteoporosis medicines who were prescribed an anti-osteoporosis medicine. Feedback from practice staff and pharmacists was explored qualitatively to evaluate the acceptability of the program. RESULTS: The proportion of patients without documented contraindications to osteoporosis therapies who were prescribed an anti-osteoporosis medicine increased significantly (134/227 [59.0 %] vs. 168/240 [70.0 %], p = 0.002). The proportion of patients for whom vitamin D and/or calcium supplement use was documented also increased significantly (145/227 [63.9 %] vs. 205/240 [85.4 %], p = 0.002). Practice staff and pharmacists were generally positive about the DUE program. CONCLUSIONS: A practice pharmacist-led DUE program improved the management of osteoporosis in general practice.
Authors: Noah Ivers; Gro Jamtvedt; Signe Flottorp; Jane M Young; Jan Odgaard-Jensen; Simon D French; Mary Ann O'Brien; Marit Johansen; Jeremy Grimshaw; Andrew D Oxman Journal: Cochrane Database Syst Rev Date: 2012-06-13
Authors: Renée Otmar; Susanne D Reventlow; Geoffrey C Nicholson; Mark A Kotowicz; Julie A Pasco Journal: Arch Osteoporos Date: 2012-07-17 Impact factor: 2.617
Authors: A Papaioannou; C C Kennedy; G Ioannidis; Y Gao; A M Sawka; D Goltzman; A Tenenhouse; L Pickard; W P Olszynski; K S Davison; S Kaiser; R G Josse; N Kreiger; D A Hanley; J C Prior; J P Brown; T Anastassiades; J D Adachi Journal: Osteoporos Int Date: 2007-10-09 Impact factor: 4.507
Authors: D Cornelissen; S de Kunder; L Si; J-Y Reginster; S Evers; A Boonen; M Hiligsmann Journal: Osteoporos Int Date: 2020-05-01 Impact factor: 4.507
Authors: Michael J Miller; Tzuchen Jou; Maria I Danila; Amy S Mudano; Elizabeth J Rahn; Ryan C Outman; Kenneth G Saag Journal: Res Social Adm Pharm Date: 2020-09-20